Hi, what are you looking for?
Jewish Business News
Search results for "Can-Fite "
Business
New OphthaliX strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases.
Business
Interim results from this Phase II/III trial and final results from the prior Phase II trial in psoriasis were both positive
StartUps
"The completion of the development of our commercial A3AR biomarker test kit comes at a very important time since we plan to use the...
Business
Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015
Business
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, reported it has received positive...
StartUps
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the Design of...
StartUps
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, treated the first patient with...
StartUps
Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a...
Business
– Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging. – CEO Pnina Fishman / Ilan Besor...
StartUps
– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin...